MedTrace Logo

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

NCT01348763 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-10-31

Study results available
· View outcomes & findings →

Summary

This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.

Conditions

Interventions

DRUG

Maraviroc

Maraviroc 150 mg daily

DRUG

Truvada

daily until 10. day then stop

DRUG

Darunavir

daily until 10. day then stop

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alan Winston, MB BH · Imperial College London

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-02-29
Completion
2012-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01348763 on ClinicalTrials.gov